GlassScriptPhysician profile
Amber M Khan
NPI 1508958471
$2,805.63
in general payments reported to CMS, 2019-2025
28 companies · $16.25 in 2025
The $16.25 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $225 · 2021: $195 · 2022: $424 · 2023: $734 · 2024: $304 · 2025: $16.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $725.52 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $429.60 | 2021-2024 | Zeposia |
| Abbvie INC. | $373.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.43 | 2019-2021 | |
| Qol Medical, LLC | $138.82 | 2023-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $135.31 | 2019-2024 | Suflave, Sutab |
| Janssen Biotech, INC. | $105.72 | 2019-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $102.68 | 2023 | Zeposia |
| Pfizer INC. | $83.97 | 2019-2024 | |
| Olympus America INC. | $78.73 | 2019 | |
| Redhill Biopharma INC. | $53.57 | 2022-2023 | |
| Lilly USA, LLC | $50.22 | 2023-2024 | Omvoh |
| Becton, Dickinson and Company | $44.77 | 2022 | |
| Intercept Pharmaceuticals, INC. | $28.57 | 2019-2022 | |
| Medtronic, INC. | $28.37 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.13 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $18.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.99 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $15.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.98 | 2019 | |
| Astellas Pharma US INC | $14.70 | 2019 | |
| Hikma Pharmaceuticals USA | $14.62 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.54 | 2019 | |
| Alfasigma USA, INC. | $14.24 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2019 | |
| Boston Scientific Corporation | $12.96 | 2019 | |
| Seqirus USA INC | $12.85 | 2019 | |
| Gilead Sciences, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.